BIRC5 and non-small cell lung carcinoma: Since intrinsic resistance to paclitaxel frequently occurs and causes treatment failure in NSCLC [16], it is conceivable to hypothesize that overexpression of DNMT1 may lead to epigenetic silencing of miRNAs to upregulate Survivin, and thereby compromise the efficacy of paclitaxel in NSCLC patients.